5Y6.F COMPASS PATHW SP.ADR
- Market cap
- EUR 1.20B
- P/E
- -
- P/B
- 8.84x
- ROE
- -161.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 5Y6.F undervalued?
Graham numberThe Graham number of COMPASS PATHW SP.ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
COMPASS PATHW SP.ADR fundamental analysis
No fundamental analysis for COMPASS PATHW SP.ADR yet.
COMPASS PATHW SP.ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About COMPASS PATHW SP.ADR
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in Augu…
Full company profileCOMPASS PATHW SP.ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
COMPASS PATHW SP.ADR annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -73.6M | -96.0M | -124M | -157M | -175M | -193M |
| EBITDA | - | -90.8M | -115M | -149M | -286M | -225M |
| Net Income | -71.7M | -91.5M | -118M | -155M | -288M | -230M |
| EPS | -1.71 | -2.15 | -1.91 | -2.26 | -3.00 | -1.62 |
| Balance Sheet | ||||||
| Total Assets | 301M | 197M | 276M | 214M | 210M | 519M |
| Total Liabilities | 16.5M | 16.0M | 50.2M | 59.0M | 263M | 377M |
| Shareholders' Equity | 284M | 181M | 226M | 155M | -52.8M | 142M |
| Cash & Short-term Investments | 273M | 143M | 220M | 165M | 150M | 444M |
| Cash Flow | ||||||
| Operating Cash Flow | -67.7M | -105M | -97.4M | -119M | -157M | -185M |
| Capital Expenditure | 334K | 596K | 66.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -68.1M | -106M | -97.4M | -119M | -157M | -185M |
| Ratios | ||||||
| ROE | -25.2% | -50.5% | -52.5% | -100.3% | - | -161.8% |
| ROA | -23.8% | -46.4% | -42.9% | -72.6% | -136.8% | -44.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
COMPASS PATHW SP.ADR dividends
COMPASS PATHW SP.ADR has not paid dividends in the last 5 fiscal years.
Who owns COMPASS PATHW SP.ADR
- Insiders 7.45%
- Institutions 72.55%
- Public & others 20.00%
- Shares outstanding 142M
- Free float 110M
COMPASS PATHW SP.ADR company profile
- Company name
- COMPASS PATHW SP.ADR
- Ticker
- 5Y6.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 156
- Fiscal year end
- December
- Address
- 33 Broadwick Street, London, United Kingdom, W1F 0DQ
- Phone
- 44 716 6766461
- Website
- compasspathways.com
About COMPASS PATHW SP.ADR
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS PATHW SP.ADR management
10- Mr. Kabir Kumar Nath M.A., M.B.A.CEO & Executive Director · born 1964
- Ms. Teri Loxam M.B.A.Chief Financial Officer · born 1973
- Dr. Guy GoodwinChief Medical Officer · born 1948
- Mr. Stephen D. SchultzSenior Vice President of Investor Relations
- Ms. Kelley BoucherChief People Officer
- Mr. Lars Christian WildeSenior Advisor · born 1986
- Dr. Susan C. Stansfield Ph.D.Advisor
- Dr. Michael Gold M.D., M.Sc.Chief Research & Development Officer · born 1961
- Ms. Lori Englebert M.B.A.Chief Commercial Officer · born 1978
- Dr. Steve Levine M.D.Chief Patient Officer